MORE-CORE trial
Jump to navigation
Jump to search
Introduction
Study characteristics:
- Manufacturer sponsored trial
- Randomized, placebo controlled
- CORE is an extension of the MORE trial[3]
- raloxifene 60 or 120 mg QD
- all received 500 mg of calcium + 400 IU vitamin D QD
- 7705 postmenopausal women with established osteoporosis
- T score < -2.5 or at least 1 vertebral fracture
- bone mineral density T scores < -2
Results:
- either dose of raloxifene reduced risk of vertebral fracture (RR 0.53-0.54)
- neither dose prevented all non-spinal fractures
- reduced risk of breast cancer (RR 0.25) group (2 vs 5 cases per 100,000 women-years)[3]
- increased risk of pulmonary embolism in raloxifene group 0.62% vs 0.16% over 8 years
More general terms
Additional terms
References
- ↑ Greenwood G. In: Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
- ↑ Cummings SR et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189, 1999 PMID: https://www.ncbi.nlm.nih.gov/pubmed/10376571
- ↑ 3.0 3.1 3.2 Journal Watch 25(2):15, 2005 Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15572757
- ↑ Prescriber's Letter 12(2): 2005 Role of Raloxifene in Breast Cancer Prevention: CORE Results Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210214&pb=PRL (subscription needed) http://www.prescribersletter.com